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Introduction
Cancer treatment is a double-edged sword, as surgery (including 
biopsy), chemotherapy, or radiation can induce tumor- dormancy 
escape and subsequent metastatic outgrowth by impairing 
tumor-specific immunity through inflammation-mediated growth 
signals and loss of resolution of inflammation (1–16). Even anes-
thetics can impair inflammation resolution (17). Recent results 
show that chemotherapy-generated cell death can paradoxically 
promote tumor growth via the release of proinflammatory and 
proangiogenic cytokines (9, 10, 18). Moreover, a preoperative 
cycle of chemotherapy can stimulate proinflammatory cytokines 
after cancer surgery (19), and surgical wounding may impair the 
efficacy of chemotherapy (20).
In the treatment of locoregional disease, the perioperative 
period offers a unique window for curbing the risk of metastatic 
growth and relapse (2, 4, 21–27). For instance, a bimodal pattern 
of recurrence for early stage breast and lung cancers suggests that 
surgery potentiates the metastatic process by inducing tumor- 
dormancy escape of micrometastatic lesions (28–30). Micro-
metastases present in cancer patients at the time of surgery are 
associated with reduced survival (31). Moreover, surgery can 
promote metastasis, not simply by mechanical dissemination of 
cancer cells, but also by stimulation of systemic inflammation and 
surgery-associated immunosuppression, resulting in outgrowth of 
dormant cancer cells at distant sites (2).
Over 30% of healthy individuals harbor microscopic dormant 
cancers (32), and noncancer surgery and anesthesia may promote 
the growth of such occult microtumors (33). Importantly, retrospec-
tive analyses of tumor recurrence in patients undergoing breast can-
cer surgery revealed that preoperative administration of ketorolac 
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tumor resection, an outcome dependent on COX-2 activity and 
host antitumor immunity as well as inhibition of COX-1–derived 
thromboxane A2 (TXA2). Moreover, preoperative acceleration of 
inflammation resolution with resolvins inhibited micrometastases 
and prevented tumor-dormancy escape. Our results indicate that 
preoperative and perichemotherapeutic interventions can control 
tumor recurrence via inflammation resolution and promotion of 
host antitumor immunity.
Results
Preoperative ketorolac eradicates micrometastases and promotes 
long-term survival in multiple tumor-resection models. To investigate 
whether preoperative ketorolac affects survival in tumor-resection 
models, we utilized a metastatic lung cancer model in which pri-
mary syngeneic Lewis lung carcinoma (LLC) tumors were grown 
to 1500–2000 mm3 in male C57BL/6J mice, resulting in microme-
tastases at the time of tumor resection (9, 52, 53). Following resec-
tion of primary tumors, control mice reproducibly succumbed to 
lung metastasis by day 24 after resection (Figure 1A). While 60% 
of mice administered preoperative ketorolac expired from macro-
scopic lung metastases by day 43, the remaining 40% exhibited 
long-term survival (defined as >90 days after tumor resection). 
In contrast, postoperative ketorolac did not prolong survival com-
pared with that of control animals, as all postoperative ketorolac- 
treated mice were moribund from spontaneous lung metastasis by 
day 25 after resection (Figure 1A).
H&E staining revealed abundant micrometastases throughout 
the lungs at the time of LLC resection (day 0) (Figure 1B). Microme-
tastases were also detected at 7 days after LLC resection in approx-
imately 60% of ketorolac-treated mice (Supplemental Figure 1A; 
supplemental material available online with this article; https://doi.
org/10.1172/JCI127282DS1). In contrast, no micrometastases were 
detected in lungs from preoperative ketorolac-treated long-term 
survivors (day 240) (Figure 1B). We conducted similar experiments 
in the highly invasive E0771 and orthotopic 4T1 breast cancer mod-
els, which metastasize to the lungs (54). Preoperative ketorolac 
resulted in long-term survival in 30% of mice at 240 days after resec-
tion compared with control mice in the E0771 model (Supplemen-
tal Figure 1B). In an orthotopic 4T1 breast cancer model in female 
BALB/cJ mice, preoperative ketorolac resulted in sustained survival 
in 40% of these mice after mastectomy (Supplemental Figure 1C). 
Thus, the antitumor activity of preoperative ketorolac is indepen-
dent of tumor type, sex, strain, or location of the primary tumor.
Ketorolac prevents surgery- and chemotherapy-induced tumor- 
dormancy escape. Systemic tumor recurrence after primary tumor 
resection can result from stimulation of dormant micrometasta-
ses present at the time of surgery (1, 2, 52), tumor cell dissemina-
tion during surgery (1, 55), or de novo tumorigenesis. To determine 
whether ketorolac can suppress surgery- or chemotherapy-induced 
tumor-dormancy escape, we utilized nonresection models in which 
mice are injected with a subthreshold (nontumorigenic) inoculum 
of 104 LLC, 104 EL4 (lymphoma), or 103 B16F10 (melanoma) tumor 
cells. Despite the presence of tumor cells, mice in this model can 
survive for over 200 days without evidence of progressive tumor 
growth, thereby mimicking tumor dormancy and minimal resid-
ual disease (9, 53, 56). Consistent with surgery-stimulated tumor 
growth (1–4), laparotomy performed distant from the primary 
was associated with a marked reduction of recurrence and mortali-
ty after surgery (34). However, ketorolac did not exhibit cancer-pre-
ventive activity when administered postoperatively, which is when 
NSAIDs are routinely administered for pain management (34). 
Preoperative ketorolac increased blood CD4+ T cells in patients 
undergoing tumor resection, potentially reversing surgery-induced 
immunosuppression during the perioperative period (35).
Chronic inflammation has been associated with tumor-pro-
moting activity (36, 37), in part due to a deficit in the resolution 
of inflammation (12). Cancer therapies have focused on block-
ing the production of COX-2–derived eicosanoids to suppress 
tumor-promoting inflammation (38). However, COX-2 is also host 
protective, as its metabolite, prostaglandin E2 (PGE2), plays a role 
in the resolution of inflammation in the chronic phase (39). Spe-
cifically, tight regulation of the temporal pattern of PGE2 release 
is critical for activating the class switching of lipid mediators from 
production of inflammatory mediators to that of proresolution sig-
nals through specialized proresolving mediators (SPMs) (40, 41). 
PGE2 released by dead cells negatively regulates an inflammato-
ry response activated by damage-associated molecular patterns, 
which may also contribute to the proresolution activity of PGE2 
(42). Other COX-2–derived prostaglandins of the D2 and J2 series 
generate lipid mediators that accelerate resolution of inflamma-
tion and control endogenous inflammation (12). Thus, COX-2 
inhibitors may be “resolution toxic,” as they suppress the produc-
tion of these prostaglandins (12, 39, 40, 43) and may worsen ther-
apy-induced cancer progression.
PGE2 also exhibits immunosuppressive activity, stimulates 
regulatory T cells, inhibits antigen presentation, and suppresses 
NK cells (36, 38). Although these functions demonstrate the role 
of PGE2 in the resolution phase of inflammation, they may inhibit 
antitumor immunity, hence promoting tumor escape (36). The dual 
activities of eicosanoids may explain the biphasic dose-dependent 
or paradoxical relationship between chronic use of NSAIDs and 
cancer risk (44). Given the opposing roles of eicosanoids, NSAIDs 
that are intended to block tumor-promoting inflammation may 
counter the resolution process and thus impose an inherent limita-
tion of efficacy. Thus, simultaneously blocking the proinflammato-
ry response and activating endogenous resolution programs may 
control cancer therapy–stimulated inflammation.
The SPM superfamily consists of potent immunoresolvent 
agonists derived from omega-3 fatty acids (e.g., resolvins, protec-
tins, and maresins) as well as arachidonic acid (e.g., lipoxins) (12, 
43, 45–47). Resolvins, lipoxins, and aspirin-triggered SPMs exhibit 
antitumor activity by promoting the clearance of therapy- generated 
tumor cell debris and counterregulating proinflammatory cyto-
kines (9, 48–51). Interestingly, unlike other synthetic nonsalicylate 
NSAIDs, aspirin irreversibly acetylates COX-2 and converts its 
enzymatic activity to produce aspirin-triggered SPMs. Thus, aspi-
rin’s mechanism of action involves both inhibition of proinflamma-
tory mediators and stimulation of proresolving mediators (12, 51).
Here, we utilize a well-established animal model in which 
dormancy escape and outgrowth of lung metastases are triggered 
by primary tumor resection to study therapeutic approaches to 
overcoming the tumor-promoting capability of surgery. We show 
that a single preoperative, but not postoperative, dose of ketorolac 
suppresses lung micrometastases present at the time of primary 
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While chemotherapeutic agents can suppress growth of 
established tumors, they can paradoxically stimulate the growth 
of a subthreshold inoculum of the identical tumor type (9, 18). 
Perichemotherapeutic administration of ketorolac neutralized 
chemotherapy-stimulated tumor growth in mice injected with 
a subthreshold inoculum of 104 tumor cells, including cisplatin- 
stimulated LLC, vincristine-stimulated EL4, and 5-fluorouracil–
stimulated (5-FU–stimulated) CT26 (colon carcinoma) (Figure 1, 
F–H). However, GFP-labeled tumor cells were detected at the 
tumor implantation site when ketorolac was administered with 
cisplatin to mice bearing LLC-GFP tumors (Supplemental Figure 
1F). Thus, ketorolac inhibited both surgery- and chemotherapy- 
induced tumor-dormancy escape.
tumor implantation site (104 cells) stimulated LLC tumor-dorman-
cy escape (Figure 1C). Preoperative ketorolac suppressed laparot-
omy-induced dormancy escape in 80% of mice by day 40 after 
tumor cell injection (Figure 1C). Similarly, preoperative ketorolac 
suppressed laparotomy-stimulated EL4 and B16F10 dormancy 
escape in 40%–60% of mice by day 22 and day 60 after tumor cell 
injection, respectively (Figure 1, D and E, and Supplemental Fig-
ure 1D). Next, we utilized GFP-labeled LLC tumor cells (104 cells) 
to monitor the impact of preoperative ketorolac on dormant tumor 
cells in mice subjected to laparotomy. Remarkably, LLC-GFP tumor 
cells were not detected at the tumor implantation site after laparot-
omy in preoperative ketorolac-treated mice (Supplemental Figure 
1E), suggesting that ketorolac eliminated dormant tumor cells.
Figure 1. Preoperative ketorolac promotes long-term survival and prevents therapy-induced dormancy escape. (A) Preoperative vs. postoperative 
ketorolac effects on survival after primary tumor resection in a spontaneous LLC metastasis model. n = 5 mice/group. Kaplan-Meier analysis log-rank test, 
*P < 0.01, control or postoperative ketorolac vs. preoperative ketorolac. (B) H&E staining of lungs from mice at the time of LLC tumor resection (day 0) or 
from preoperative ketorolac-treated mice at 240 days after resection. Representative micrographs of 10 mice/group. Scale bars: 50 μm. (C–E) Growth of 
LLC, EL4, or B16F10 in mice treated with preoperative ketorolac or control subjected to laparotomy (day 0, 21, and/or 42 after injection) vs. no laparotomy. 
n = 10–20 mice/group. Two-way repeated measure mixed-effects ANOVAs for tumor growth rates and 2-tailed Student’s t test for final tumor measure-
ments were used throughout unless specified. (C) *P < 0.001, laparotomy vs. no laparotomy; **P < 0.001, laparotomy and ketorolac vs. laparotomy. (D)  
*P = 0.009, laparotomy and ketorolac vs. laparotomy; **P < 0.001, laparotomy vs. no laparotomy. (E) *P < 0.05, laparotomy and ketorolac vs. laparoto-
my; **P < 0.05, laparotomy vs. no laparotomy. (F–H) Growth of LLC, EL4, or CT26 (104 cells) in response to chemotherapy and/or ketorolac. Ketorolac was 
administered the day before, day of, and day after chemotherapy. Systemic chemotherapy was initiated on day of tumor cell injection. (F) n = 15–28 mice/
group. *P < 0.001, cisplatin and ketorolac vs. cisplatin (day 36 after injection). (G) n = 5 mice/group. *P < 0.05,  control or vincristine and ketorolac vs. 
vincristine (day 30 after injection). (H) n = 5 mice/group. *P < 0.01, control or 5-FU and ketorolac vs. 5-FU (day 25 after injection).
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ketorolac resulted in no long-term survivors (Figure 2C). To con-
firm that COX-2 inhibition may impair the activity of preoperative 
ketorolac, we next performed the LLC tumor-resection experi-
ments in COX-2–KO mice. While preoperative ketorolac resulted 
in long-term survival after resection in WT mice, long-term surviv-
al was not observed in COX-2–KO mice (Figure 2D). Moreover, the 
combination of preoperative ketorolac and an anti-PGE2 neutraliz-
ing antibody did not result in any long-term survivors after resec-
tion (Figure 2E). Therefore, in the LLC tumor-resection model, 
baseline COX-2 activity and PGE2 levels may be necessary for the 
antitumor activity of ketorolac.
Since COX-1 preferentially mediates TXA2 production (38, 
61), we measured plasma TXB2, a stable hydration product of 
TXA2 used to assess COX-1 activity. Profiling based on liquid chro-
matography–tandem mass spectrometry (LC-MS/MS) revealed 
dramatic reduction of TXB2 at 2 hours after LLC resection as well 
as a lesser reduction in PGE2 in ketorolac-treated mice compared 
with control (Figure 3, A and B). To ascertain a functional role 
for TXA2 in the observed antitumor activity of ketorolac, we per-
formed primary tumor resections in mice lacking the thrombox-
ane prostanoid (TP) receptor. TP-KO mice exhibited long-term 
survival compared with WT mice (Figure 3C). Moreover, preoper-
ative administration of the highly specific, high-affinity TP-TXA2 
antagonist terutroban also resulted in prolonged survival after 
LLC resection in 40% of mice (Figure 3D). Conversely, the TP 
COX-1/TXA2 inhibition and basal COX-2 activity are critical 
for the antitumor activity of ketorolac. Among the FDA-approved 
NSAIDs, ketorolac preferentially inhibits COX-1 and exhibits 
lower COX-2 activity (57, 58). To determine whether the observed 
antitumor activity of preoperative ketorolac was mediated by 
COX-1 and/or COX-2 inhibition, we utilized 3 highly selective 
COX-1 inhibitors (SC-560, FR122047, or TFAP), the selective 
COX-2 inhibitor celecoxib, and the nonselective COX inhibitor 
indomethacin (38, 59). Similar to ketorolac, preoperative admin-
istration of the selective COX-1 inhibitors resulted in long-term 
survival in 40%–50% of mice up to 230 days after LLC resection 
(Figure 2A). However, celecoxib did not result in sustained surviv-
al (Figure 2B), suggesting that the observed antitumor activity of 
ketorolac is likely mediated by COX-1 inhibition.
Although indomethacin prolonged survival compared with 
control, no long-term survivors after LLC resection were noted 
(Figure 2A). A similar response profile of antitumor activity was 
observed with other nonselective NSAIDs, such as diclofenac, 
ibuprofen, and high-dose aspirin (30 mg/kg) (Figure 2B). Aspirin 
can prevent metastasis by inhibiting COX-1 activity and subse-
quent TXA2 synthesis (60, 61). Low-dose aspirin prolonged sur-
vival compared with high-dose aspirin (which engenders more 
complete inhibition of COX-2) (Figure 2B), suggesting that pre-
operative COX-2 inhibition may negate the anticancer activity of 
ketorolac. Indeed, preoperative coadministration of celecoxib and 
Figure 2. COX-1 inhibition and baseline COX-2 activity are critical for the antitumor activity of ketorolac. (A) Preoperative COX-1 inhibitors (FR122047, 
TFAP, or SC-560), ketorolac, or nonselective COX inhibitor (indomethacin) effects on survival after LLC resection. n = 4–6 mice/group. *P < 0.05, FR122047, 
TFAP, SC-560, ketorolac, or indomethacin vs. control. (B) Preoperative NSAIDs effect on survival after LLC resection. n = 4–5 mice/group. *P = 0.003, 
SC-560 vs. control; **P < 0.05, ketorolac or aspirin (10 mg/kg) vs. control. (C) Preoperative celecoxib and/or ketorolac effects on survival after LLC resec-
tion. n = 4–6 mice/group. *P < 0.05, ketorolac, celecoxib, or ketorolac and celecoxib vs. control. **P < 0.05 ketorolac or celecoxib vs. ketorolac and celecox-
ib. (D) Preoperative ketorolac vs. celecoxib effects on survival after LLC resection in WT or COX-2–KO mice. n = 4–9 mice/group. *P < 0.05, WT ketorolac vs. 
COX-2 KO ketorolac. (E) Preoperative ketorolac and/or PGE2 depletion effects on survival after LLC resection. n = 5–6 mice/group. *P < 0.05, ketorolac, PGE2 
neutralizing antibody, or ketorolac and PGE2 neutralizing antibody vs. control. **P < 0.01, ketorolac vs. ketorolac and PGE2 neutralizing antibody.
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plemental Figure 2). This broad lipidomic shift indicates a complex 
balance between pro- and antitumorigenic mediators (53), which 
may account for the observed subset of ketorolac-treated mice that 
developed invasive lung metastasis (Figure 1A). Notably, lipoxin 
A4 (LXA4) was increased in the plasma of preoperative ketorolac- 
treated mice after LLC resection (Figure 4A). Since LXA4 is an SPM 
(12), we reasoned that the balance of inflammation regulation may 
be tipped toward resolution, thereby either enhancing or recapitu-
lating the antiinflammatory and proresolving activity of ketorolac. 
Indeed, SPMs, such as lipoxins and resolvins, possess potent anti-
tumor activity in experimental models (9, 48–51, 62).
To determine whether stimulation of inflammation resolution 
could prevent tumor recurrence and/or suppress outgrowth of 
micrometastases, we administered resolvins via osmotic pump 2 
hours prior to tumor resection. Preoperative resolvin D2 (RvD2) 
prolonged survival after tumor resection and was more potent 
in preventing metastasis than RvD2 administered at the time of 
surgery (Figure 4B). Specifically, preoperative administration of 
resolvins (RvD2, RvD3, or RvD4) resulted in 50%–80% survival 
at 37 days after resection, with RvD2 exhibiting the most potent 
antitumor activity (Figure 4C).
Since low-dose aspirin triggers the production of resolvins from 
omega-3 fatty acids (12), we treated mice with low-dose aspirin in 
combination with an omega-3 fatty acid diet and found increased 
survival, but no long-term survivors (Figure 4D). Although aspirin 
receptor agonist U-46619 accelerated morbidity from lung metas-
tasis compared with control and abrogated the antitumor activity 
of ketorolac (Figure 3D). Since TXA2 stimulates platelet aggre-
gation (38, 61), we also evaluated the activity of the antiplatelet 
agent clopidogrel. Preoperative clopidogrel prolonged survival 
after LLC resection compared with control, resulting in 20% long-
term survivors (Figure 3D). Similarly to preoperative ketorolac, no 
micrometastases were detected in the lungs of long-term survivors 
administered preoperative terutroban or clopidogrel on day 180 
after LLC resection (Figure 3, E and F). Selective COX-2 inhibitors 
do not affect platelet TXA2 production and may not directly impair 
platelet aggregation (38, 60). Collectively, these results suggest 
that the antitumor activity of ketorolac is in part driven by COX-1/
TXA2 inhibition and subsequent reduction in platelet aggregation 
and accompanying degranulation.
Preoperative resolvins eradicate micrometastases and inhibit 
tumor-dormancy escape. LC-MS/MS analysis of plasma from preop-
erative ketorolac-treated mice after LLC resection demonstrated a 
global shift in the lipid-mediator profile (Supplemental Figure 2). 
Not only were COX-dependent and nonenzymatic oxidation prod-
ucts affected, but there was also shunting of the arachidonic acid 
cascade to the lipoxygenase (LOX) and cytochrome P450 (CYP) 
pathways. Specifically, ketorolac increased LOX-derived 12-oxo-
ETE and 13-HODE as well as the tumorigenic CYP450-derived 
5,6-EET, 11,12-EET, and 10,11-EDP compared with control (Sup-
Figure 3. COX-1/TXA2 inhibition mediates the antitumor activity of ketorolac. LC-MS/MS–based analysis of (A) TXB2 or (B) PGE2 in plasma 2 hours after 
LLC resection from control or preoperative ketorolac-treated mice. n = 5 mice/group. *P < 0.05 vs. control. (C) Survival of TP KO mice vs. WT mice after LLC 
resection. n = 5 mice/group. *P = 0.002, WT vs. TP KO mice. (D) Preoperative clopidogrel, terutroban, U-46619, and/or ketorolac effects on survival after 
LLC resection. n = 4–5 mice/group. *P < 0.01, ketorolac, terutroban or clopidogrel vs. control. **P = 0.005 U-46619 vs. ketorolac. H&E staining of lungs 
from preoperative (E) terutroban-, or (F) clopidogrel-treated mice at 180 days after LLC resection. Scale bars: 50 μm.
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or omega-3 fatty acid diet alone exhibited less antitumor activity 
than the combination treatment, survival was prolonged compared 
with that of mice fed an omega-6 fatty acid diet. The omega-6 fat-
ty acid diet alone accelerated progression and shortened median 
survival in mice from 19 days (control, Figure 2, A and B) to 16 days 
(Figure 4E) after resection, consistent with studies suggesting that 
dietary omega-6 fatty acids can promote tumor progression and 
metastasis (53). Moreover, the omega-6 fatty acid diet alone mark-
edly shortened survival compared with combinations with aspirin, 
RvD2, and/or ketorolac (Figure 4E).
The potent antitumor activity of low-dose aspirin combined 
with omega-3 fatty acids offered the opportunity to examine wheth-
er promotion of resolution of inflammation could synergize with the 
antiinflammatory activity of ketorolac. Intriguingly, preoperative 
ketorolac in combination with low-dose aspirin and omega-3 fatty 
acid diet resulted in 90% survival at 110 days after resection (Figure 
4D). The combination of preoperative ketorolac and resolvins led to 
long-term survival after resection in 70% of mice administered the 
omega-6 fatty acid diet (Figure 4E). Tumor cells were undetectable 
in H&E-stained sections of lungs from long-term survivors treated 
with preoperative RvD2 or the combination of low-dose aspirin, 
omega-3 fatty acids, and ketorolac (day 180) (Figure 4, F and G).
To determine whether the antitumor activity of resolvins 
extended to a surgery-induced tumor-dormancy escape model, 
we injected 104 EL4 into mice and performed a laparotomy, which 
triggered dramatic tumor outgrowth. Preoperative RvD2 prevent-
Figure 4. Preoperative resolvins eliminate micrometastases and prevent surgery-stimulated dormancy escape. (A) LC-MS/MS–based analysis of LXA4 in 
plasma 2 hours after LLC resection from control or preoperative ketorolac-treated mice. n = 5 mice/group. *P < 0.05 vs. control. (B) Preoperative vs. periop-
erative RvD2 effects on survival after LLC resection. n = 5 mice/group. *P < 0.05, preoperative RvD2 vs. perioperative RvD2. (C) Preoperative resolvins 
effects on survival after LLC resection. n = 5 mice/group. *P < 0.05, RvD2 or RvD3 vs. control. (D and E) Preoperative omega-3 or omega-6 fatty acid 
diet and/or low-dose aspirin (10 mg/kg/d) effects on survival after LLC resection. Diet and aspirin were administered 7 days before and 3 days after LLC 
resection and preoperative ketorolac. n = 5 mice/group. *P < 0.05 vs. omega-6 fatty acid diet. H&E staining of lungs from mice treated with preoperative 
(F) RvD2 or (G) ketorolac, low-dose aspirin, and omega-3 fatty acid diet on day 180 after LLC resection. n = 4–5 mice/group. Scale bars: 50 μm. (H) Growth 
of EL4 (104 cells) after preoperative RvD2 and laparotomy. n = 5–10 mice/group. *P < 0.05, laparotomy vs. no laparotomy; **P < 0.05, laparotomy and RvD2 
vs. laparotomy.
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ed surgery-induced EL4 tumor-dormancy escape (Figure 4H). 
Thus, preoperative stimulation of inflammation resolution with 
resolvins may inhibit surgery-induced tumor recurrence.
The antitumor activity of ketorolac is T cell dependent and impaired 
by chemotherapy. Inflammation plays a multifaceted role in regulating 
the adaptive immune response. For example, prostaglandins, such 
as PGE2, suppress acute inflammatory mediators, activate dendrit-
ic cells, sensitize T cells to eliminate infection, and promote T cell 
exhaustion (36, 42). Moreover, adaptive antitumor immunity has 
been implicated in the regulation of metastatic tumor dormancy (63, 
64). These facts, along with the absence of tumor cells in the lungs of 
long-term survivors, led us to examine whether the immune system 
Figure 5. Ketorolac restores antitumor immunity. (A) Preoperative ketorolac effects on survival of SCID or C57BL/6J mice after LLC resection. n = 5–10 
mice/group. *P = 0.04, C57BL/6J ketorolac vs. C57BL/6J control; **P = 0.004, SCID control vs. C57BL/6J control (day 14 after resection). (B) Growth of EL4 
(104 cells) after preoperative ketorolac and/or laparotomy in SCID and C57BL/6J mice. Laparotomy was performed on day 0. n = 5–10 mice/group. *P < 
0.05, C57BL/6J (laparotomy and ketorolac) vs. C57BL/6J (laparotomy). (C) Percentage of control or preoperative ketorolac-treated C57BL/6 or RAG1-KO 
mice demonstrating LLC tumor-dormancy escape. Laparotomies were performed on days 0, 21, and 42 after injection. n = 5–10 mice/group. *P < 0.05, WT 
(laparotomy and ketorolac) vs. WT (laparotomy). (D) Preoperative ketorolac effects on survival of athymic mice after LLC resection. n = 3–4 mice/group. 
(E) Preoperative ketorolac and T cell depletion effects on survival after LLC resection. T cell–depleting (CD4+ or CD8+) antibodies or control (rat IgG2b) were 
administered 3 days before tumor resection, the day of tumor resection, and every 3 days thereafter for 2 weeks. n = 5 mice/group. *P < 0.05, control 
(IgG); CD4+ and CD8+ depletion and ketorolac; CD4+ depletion and ketorolac or CD8+ depletion and ketorolac vs. ketorolac. (F) Expression of FOXP3, CD4, 
and CD8 (brown DAB staining) in spleens from preoperative ketorolac-treated vs. control mice on day 5 after LLC resection. Scale bar: 100 μm. Immune cell 
quantification is represented as mean ± SEM. n = 4–5 mice/group. *P < 0.05 vs. control.
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T cell subtypes are necessary for the ketorolac-induced antitumor 
response. Immunohistochemistry revealed increased CD8+ and 
CD4+ T lymphocytes and decreased cells positive for the regula-
tory T cell marker FOXP3 in the spleen and lung tissues of ketoro-
lac-treated mice on days 5 and 7 after resection, respectively, as 
compared with control mice (Figure 5F and Supplemental Figure 
3A). RvD2 also increased CD8+ T lymphocytes in the lung tis-
sues of mice (day 180 after resection) (Supplemental Figure 3B). 
Therefore, the antitumor activity of ketorolac and resolvins may 
be mediated by activation of CD4+ and/or CD8+ T cells.
Since checkpoint inhibitors such as anti-programmed cell 
death protein 1 (anti-PD1) antibody can augment cytolytic T 
cell responses, we hypothesized that preoperative ketorolac and 
immune-checkpoint blockade may act synergistically in our 
resection models. Indeed, this combination resulted in synergistic 
antitumor activity, with approximately 80% of animals exhibiting 
long-term survival in both syngeneic LLC and EL4 tumor-resec-
tion models (Figure 6, A and B). While ketorolac alone exhibited 
antitumor activity that was further enhanced by anti-PD1 treat-
plays a role in the antitumor activity of ketorolac. Preoperative ketoro-
lac prolonged survival in 60% of immunocompetent C57BL/6J mice 
up to 120 days after LLC resection (Figure 5A). In contrast, ketoro-
lac did not improve survival after resection in SCID mice, which lack 
functional B and T lymphocytes (Figure 5A). SCID mice exhibited a 
drastically shortened baseline survival in the LLC tumor-resection 
model, with a median overall survival of 10 days compared with 25 
days in C57BL/6J mice (Figure 5A). Similarly, ketorolac did not affect 
laparotomy-induced tumor-dormancy escape in immunodeficient 
SCID or RAG1-KO mice (Figure 5, B and C).
To investigate the specific role of T cells in the antitumor 
activity of ketorolac, we utilized nude athymic mice in a C57BL/6J 
background. The antitumor activity of ketorolac was abrogated in 
these mice, as all of the ketorolac-treated mice succumbed to lung 
metastasis by day 22 after LLC resection (Figure 5D). To confirm 
that the observed antitumor activity of ketorolac was T cell medi-
ated, we depleted CD8+ and/or CD4+ T cells in vivo using neutral-
izing antibodies. T cell depletion of either subtype abolished the 
antitumor activity of ketorolac (Figure 5E), confirming that both 
Figure 6. Antitumor activity of ketorolac is mediated by T cell immunity. (A and B) Preoperative ketorolac and immune checkpoint blockade (anti–PD-1) 
on survival after tumor resection (LLC or EL4). Anti–PD-1 (200 μg/mouse q 3 days for 60 days). n = 5–10 mice/group. (A) *P = 0.002, ketorolac and anti–
PD-1 vs. control (IgG) or anti–PD-1 alone. (B) *P < 0.05, control (IgG), ketorolac and control (IgG), or anti–PD-1 vs. ketorolac and anti–PD-1. (C) Preoperative 
ketorolac and/or anti–PD-1 (1 dose, 200 μg/mouse) effects on spontaneous LLC lung metastasis at 24 days after LLC resection. n = 4 mice/group. Images 
show representative lung metastasis in preoperative ketorolac and/or anti–PD-1, and control mice. Scale bar: 1 cm. Bar graph is presented as lung weight 
(g) ± SEM per group. *P = 0.002, ketorolac vs. control; **P < 0.001, ketorolac and anti–PD-1 vs. anti–PD-1. (D) Preoperative ketorolac-treated C57BL/6J  
mice that survived 90 days after LLC resection were injected with 106 LLC and compared with naive control mice. Ninety days later, ketorolac-treated mice 
were rechallenged with 106 B16F10. *P < 0.05, ketorolac vs. control. LLC tumor growth (106 cells) after adoptive cell transfer of (E) splenocytes or (F) isolated 
CD8+ T cells from preoperative ketorolac-treated long-term survivors (90 days) after LLC resection or naive control mice. n = 3–5 mice/group. (E and F)  
*P < 0.05, ketorolac vs. control.
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100 days after injection. When these mice were injected with a sec-
ond syngeneic tumor type (106 B16F10), they exhibited rapid tumor 
growth (Figure 6D), suggesting tumor-specific immunity. Similarly, 
preoperative ketorolac-treated long-term survivors in the postlapa-
rotomy and postchemotherapy LLC tumor-dormancy escape models 
were resistant to LLC challenge, but exhibited rapid tumor growth 
when challenged with B16F10 tumor cells (Supplemental Figure 4, 
A and B). Moreover, preoperative RvD2-treated long-term survivors 
after LLC resection were also resistant to LLC rechallenge for over 
ment, anti-PD1 alone did not exhibit antitumor activity in these 
models (Figure 6, A–C). Moreover, preoperative ketorolac alone or 
in combination with anti-PD1 suppressed lung metastasis on day 
24 after LLC resection (Figure 6C).
To corroborate the antitumor immunity stimulated by ketorolac, 
we assessed immunological memory by rechallenging long-term 
survivors administered ketorolac prior to tumor resection with the 
identical tumor type (106 LLC cells). These long-term survivors were 
resistant to LLC rechallenge, as no visible tumors were observed over 
Figure 7. ScRNA-Seq analysis demonstrates an altered immune landscape in response to ketorolac. ScRNA-Seq analysis on splenic cells isolated from 
preoperative ketorolac-treated or control mice 7 days after LLC resection. n = 2 mice/group throughout. (A) 2D visualization of single-cell clusters generated 
using the tSNE approach from normalized data of 2429 ketorolac-treated and 1864 control splenic cells. Cell clusters were annotated based on expression of 
established immune cell markers, e.g., T cells (Cd3d+), exhausted T cells (Pdcd1, Ctla4, Lag3, Entpd1, and TIM3), T memory cells (Il7r, Ccr7, Sell, CD44), B cells 
(Cd19+), dendritic cells (Itgax), and macrophages (Adgre1) (left panel). Chart depicts relative proportions of cells in the clusters from each sample (right panel). 
(B) Percentage of cells from control and ketorolac-treated mice, per cluster. (C) Preoperative ketorolac effects on the immune landscape of T cells. Feature 
maps depict the expression of T cell (Cd3d+), exhausted T cell (Pdcd1), and memory T cell (Il7r) markers for each cell cluster on the tSNE map. Cells from ketoro-
lac-treated and control samples are shown as solid dots and triangles, respectively. Bar plots depict the relative proportions of T cell subpopulations in control 
and ketorolac-treated single-cell profiles. (D) Heatmap depicts the activation or inhibition of key regulators in the control and ketorolac-treated T cell clusters. 
Regulators were calculated based on Z scores using an upstream regulator analysis module in ingenuity pathways analysis systems.
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tration of chemotherapy would also influence preoperative ketoro-
lac-treated long-term survivors. Ketorolac-treated mice surviving 
over 90 days after LLC resection were subjected to 3 cycles of cis-
platin (5 mg/kg q 5 days) and then rechallenged with LLC tumor 
cells. This challenge resulted in a rapid onset of LLC tumor growth 
in the ketorolac-treated as well as control mice (Supplemental Fig-
ure 6C). Therefore, adjuvant chemotherapy, even when admin-
istered a few weeks after tumor resection, may interfere with the 
antitumor immunity of preoperative ketorolac.
Single-cell profiling of immune cell populations in response to 
ketorolac. To characterize the ketorolac-mediated immunomod-
ulatory response, we utilized droplet-based single-cell RNA-Seq 
(scRNA-Seq) to obtain single-cell resolution transcriptomes of 
splenic tissues from control and ketorolac-treated mice on day 7 
after LLC resection. The transcriptome profiles of 1864 and 2429 
individual cells from spleens of 2 control and 2 ketorolac-treated 
mice, respectively, revealed that ketorolac modulated the immune 
landscape by altering the relative abundance and transcriptome 
profiles of T cells and granulocytes. Standard cluster analysis of 
cells based on their most variably expressed genes in the scRNA-
Seq transcriptomes is shown in the projection of gene expression 
space onto a single 2D space using t-distributed stochastic neigh-
bor embedding (tSNE) (Figure 7A). The 2D plot contains cells 
90 days after injection, yet developed aggressive tumor growth when 
injected with B16F10 (Supplemental Figure 4C). To confirm that 
the antitumor activity of ketorolac may be mediated by CD8+ T cell 
activation, we performed adoptive transfer of immune cells from pre-
operative ketorolac-treated long-term survivors after LLC resection 
into naive mice. Splenocyte or CD8+ T cell transfer from long-term 
ketorolac-treated survivors inhibited LLC growth compared with that 
of control mice that received splenocytes or CD8+ T cells from naive 
mice (Figure 6, E and F, and Supplemental Figure 5, A–D).
Cancer patients undergoing tumor resection often receive 
adjuvant chemotherapy, as perioperative chemotherapy may be 
most effective when administered before surgery, at the time of 
surgery or soon after surgery (65, 66). Thus, we determined wheth-
er administration of chemotherapy after preoperative ketorolac 
would affect survival and antitumor immunity after tumor resec-
tion. A single dose of cisplatin on day 7 after LLC resection abrogat-
ed the long-term survival observed in the preoperative ketorolac 
group (Supplemental Figure 6A). Immunohistochemistry revealed 
that chemotherapy following preoperative ketorolac reduced the 
number of CD4+ and CD8+ T cells compared with preoperative 
ketorolac alone on day 7 after LLC resection (Supplemental Fig-
ure 6B). Adjuvant chemotherapy is typically administered 4 to 6 
weeks after surgery. We therefore asked whether delayed adminis-
Figure 8. Key regulators in granulocytes/neutrophils from preoper-
ative ketorolac-treated and control mice. Spleens from preoperative 
ketorolac-treated and control mice are identical to those used in Figure 
7. (A) Feature and bar plots highlight the proportion of Ly6g+- and 
Mmp9-producing granulocytes/neutrophils in spleens from ketoro-
lac-treated or control mice. (B) Interactive network of key regulators 
significantly activated in granulocytes/neutrophils from control mice. 
Bar graph depicts Z score (>1.5 = activation, < 1.5 = inhibition) of NF-κB 
and PI3K complexes in control and ketorolac-treated samples based on 
expression of genes in the granulocyte/neutrophil cluster.
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portion of Mmp9-expressing Ly6g+ cells was significantly higher in 
the spleens of control compared with ketorolac-treated mice (Fig-
ure 8A). MMP9 is a critical protein that promotes the expansion of 
Ly6g+ myeloid-derived suppressor cells (71). Moreover, upstream 
regulator analysis (68) of the granulocyte cluster indicated that 
NF-κB and PI3K were significantly activated in granulocytes from 
control mice compared with ketorolac-treated mice (Figure 8B), 
which is consistent with the suppressive activity of NSAIDs (72). 
The pathways and functions enrichment analysis also depicted 
alterations in triacylglycerol, carbohydrate, and lipid metabolism in 
ketorolac-treated granulocytes (Supplemental Table 1). We specu-
late that the low PI3K activity in the ketorolac-treated samples may 
decrease glycolysis (73), the major pathway of energy generation for 
granulocytes (74), and diminish migration (75).
Discussion
Here, we demonstrate that preoperative, but not postoperative, 
ketorolac and/or resolvins eradicate micrometastases in multi-
ple tumor-resection models. While we cannot exclude minimal 
residual disease due to individual disseminated malignant cells, 
the elimination of metastatic recurrence by preoperative ketorolac 
resulted in long-term survival after tumor resection. These inter-
ventions also prevented dormancy escape induced by surgery or 
chemotherapy in several tumor types. The antitumor activity of 
ketorolac is dependent on a T cell–mediated response, as its activ-
ity was enhanced by immune checkpoint blockade and abrogat-
ed in athymic mice. Consistent with the immunohistochemistry, 
single- cell transcriptomics demonstrated increased CD4+ and 
CD8+ T cells in the spleens of ketorolac-treated mice as well as a 
shift in the proportions of T cell subtypes, indicating an increase 
in memory T cells and reduction of exhausted T cells. The T cell 
response may be specific for tumor cells, since ketorolac-treated 
mice were protected against a secondary challenge with the same 
tumor type, but not from an unrelated type. Moreover, adoptive 
transfer confirmed that the protective antitumor activity of ketoro-
lac was T cell mediated, as no tumor growth was observed in mice 
that received T cells from ketorolac-treated long-term survivors. 
Therefore, targeting cancer therapy–induced inflammation with 
preoperative ketorolac and/or resolvins may reduce tumor recur-
rence and metastatic outgrowth via a T cell response.
Our study provides insight into the multifaceted roles of 
cyclooxygenase enzymes and their products in tumor biology. 
Specifically, we establish the importance of inhibiting COX-1 
while maintaining COX-2 activity to control tumor recurrence 
or metastasis. These results shed light on the conceptual frame-
work of inflammation and adaptive immunity in cancer. For 
instance, COX inhibition is generally thought to contribute to 
the prevention and control of tumor growth (38, 76). In the con-
text of surgery, the NSAID meloxicam was recently reported to 
suppress dormancy escape of micrometastatic lesions in mouse 
models (2). However, we show that COX-2 inhibition may hinder 
the antitumor activity of ketorolac via impairment of the resolu-
tion of inflammation. In fact, selective COX-2 inhibitors have not 
improved recurrence-free survival in the clinic (77–81). Rather, 
chronic COX-2 inhibition or NSAIDs (e.g., sulindac) are linked to 
increased risk of breast and hematological cancers and can result 
in resistant adenomas and breakthrough carcinomas (82, 83). 
from both ketorolac-treated and control samples analyzed as 1 
concatenated data set. Analysis of marker genes assigned the 17 
identified robust clusters to T cells, B cells, erythroid cells, NK 
cells, granulocytes, neutrophils, macrophages, and dendritic cells 
(Figure 7A). Only 1 cell cluster was mouse specific and unrelated to 
treatment, while the majority of clusters were formed by all mice 
and represent known cell types — indicating minimal batch or 
mouse effect (Figure 7A). Ketorolac-treated spleens differed from 
control in relative cell-type abundance and gene expression states 
of individual cells.
At the level of cell-type abundance, with the exception of 
a few clusters that contained only or predominantly cells from 
control samples, the clusters contained varying proportions from 
both control and ketorolac-treated mice (Figure 7B). In both mice, 
ketorolac increased the fraction of splenic Cd3d+ T cells compared 
with those of control, from 9.12% to 19.1% (clusters 1 and 13 in Fig-
ure 7A). One T cell cluster (cluster 13 in Figure 7A) was enriched 
in exhausted T cells (as determined by expression of markers 
PD1, CTLA4, and TIM3) from 1 control mouse, while both ketoro-
lac-treated mice had low numbers of exhausted T cells (Figure 7, B 
and C). Moreover, the proportion of memory T cells (IL7r+) (clus-
ter 1 in Figure 7A) increased from 32% in the 2 control spleens to 
52% in the 2 ketorolac-treated spleens (Figure 7C). Although T 
cell–subtype abundance varies considerably between individuals 
(67), this finding is consistent with systemic activation of T cell 
immunity in the ketorolac-treated mice. This constellation sug-
gests that ketorolac may improve T cell antitumor immunity and 
the presence of exhausted PD1+ T cells is consistent with ketoro-
lac’s synergism with an anti-PD1 inhibitor (Figure 6, A and B).
At the transcriptome level within the T cell clusters, shifts 
in cell phenotypic states of control and ketorolac-treated mice 
(enrichment of cells from 1 mouse in a subregion of a cluster, 
Figure 7A) are apparent in the tSNE plots. Utilizing a systematic 
quantitative analysis, we focused on T cells and identified genes 
that were significantly enriched in each cluster (P < 0.01) and then 
performed a pathway analysis on these genes for the control and 
ketorolac-treated mice independently. Such gene ontology anal-
ysis suggested that distinct upstream regulators are significantly 
activated or inhibited in the different T cell clusters from control 
and ketorolac-treated mice (Figure 7D). The upstream regulator 
analysis (68) on genes associated with the exhausted T cell clus-
ter in the control spleens indicated states controlled by transcrip-
tion factor GATA3 and the cytokine VEGFA, which are associated 
with angiogenesis and Th2 polarization (69). In contrast, the same 
analysis in spleen cells from ketorolac-treated mice suggested acti-
vation of a state under control of the transcription factor 7 (TCF7) 
and the cytokines TNF-α, IFN-γ, and IFN-α (Figure 7D), which are 
associated with activated cytotoxic T cells. Of note, TCF7, which is 
associated with memory T cells and implicated in rescuing T cells 
from exhaustion by anti–PD-1 therapy (70), was activated in the 
CD8+ T cells of ketorolac-treated mice.
In addition, scRNA-Seq analysis demonstrated reduced Ly6g+ 
granulocytes in spleens of both ketorolac-treated mice (35 out of 
2429 cells, 1.4%) as compared with the control mice (65 out of 1864 
cells, 3.5%) (Figure 8A, cluster 12 in Figure 7A). A significant glob-
al shift in gene expression profiles of granulocytes from ketorolac- 
treated versus control mice was not observed. However, the pro-
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surgery was detrimental to achieving effective antitumor T cell 
immunity, which may be due to cytotoxicity on proliferating T 
cells. Even when administered several weeks after resection, che-
motherapy appears to abrogate T cell memory and may increase 
the likelihood of recurrence. Fifth, dormant tumor cells are typ-
ically resistant to adjuvant chemotherapy (98), and chemother-
apy can awaken dormant micro metastases. Although we did 
not specifically study the combination of resolvins and ketoro-
lac with chemotherapy, tumor-dormancy escape was inhibited 
in a subset of mice when ketorolac was administered alongside 
chemotherapy (Figure 1, F–H). We also found via LC-MS/MS–
based profiling that ketorolac stimulated an increase in plasma 
LXA4. Moreover, systemic treatment with resolvins inhibits che-
motherapy-stimulated tumor growth in multiple tumor models 
(9). Collectively, our data suggest that flanking chemothera-
py with antiinflammatory or proresolution therapies may be a 
novel approach for cancer treatment. Sixth, cancer patients in 
remission may benefit from preoperative ketorolac or resolvins 
prior to surgery, since surgery or even biopsy can induce tumor- 
dormancy escape or metastasis (1, 6, 8). The relapse pattern fol-
lowing delayed reconstructive surgery in breast cancer patients 
is bimodal, suggesting a systemic action on dormant micro-
metastases from surgery (30). Seventh, although it may be 
tempting to enroll patients at highest risk for recurrence in trials 
of ketorolac or resolvins, these patients are likely to receive neo-
adjuvant or adjuvant chemotherapy, radiation (encompassing 
draining lymph nodes), and/or have their draining lymph nodes 
resected per current clinical guidelines. These interventions may 
counteract the induction of an effective T cell immune response. 
It may therefore be prudent to first conduct small biomarker 
endpoint studies to assess the impact of preoperative ketorolac 
and/or resolvins on T cell response via monitoring activation of 
CD8+ cells after surgery, T cell response to predicted neoanti-
gens, T cell receptor diversity, or single-cell sequencing. Thus, if 
neoadjuvant chemotherapy negates an antitumor T cell response 
despite administration of preoperative ketorolac, such patients 
would then be excluded from a randomized prospective study.
Collectively, our data suggest a paradigm shift in clinical 
approaches to resectable cancers. Over the last century, the 
field has evolved from a “more is better” Halstedian stance with 
increasingly radical surgeries to a view of early stage cancer as a 
systemic disease, resulting in the adoption of adjuvant and neo-
adjuvant chemotherapy. Now, we and others (2) are showing that 
it may be possible to eradicate micrometastatic disease and dor-
mant tumor cells without chemotherapy. Here, we demonstrate 
that unleashing T cell immunity by preoperative suppression 
of systemic inflammation or stimulation of inflammation res-
olution exhibits potent antitumor activity, even curing mice of 
micrometastases. Pharmacological enhancement of resolution 
via exogenous resolvins (demonstrated here with RvD2, RvD3, 
and RvD4) at ng/d doses or omega-3 fatty acid supplementation 
restores endogenous SPMs. Moreover, ketorolac and resolvins 
demonstrate synergistic antitumor activity. Thus, simultaneously 
blocking proinflammatory responses with ketorolac and activat-
ing endogenous resolution programs via resolvins may represent a 
novel approach for preventing systemic recurrence in the context 
of locoregional disease.
Moreover, while a combination of COX-2 inhibitors with adju-
vant temozolomide following resection of glioblastoma extend-
ed progression-free survival, the COX-2 inhibitors also increased 
the rate of metastasis (84).
In addition, COX-2–derived PGE2 exhibits complex and 
opposing activities. PGE2 has been implicated in the suppression 
of antitumor immunity (85–87), as it can hinder antigen presen-
tation, inhibit T cell and NK cell effector functions, and promote 
the activity of regulatory T cells (36, 85, 88). In contrast, PGE2 may 
be necessary for optimal CD8+ T cell response (38, 89), support-
ing our finding that baseline COX-2 is critical for the antitumor 
immune response of ketorolac. PGE2 also plays a critical role in 
the termination of inflammation, as it is required for a bioactive 
lipid-class switching to generate SPMs that promote the resolu-
tion of inflammation (40). The proresolution activities of PGE2 on 
both the innate and adaptive immune system (12) may explain why 
selective COX-2 inhibition with celecoxib impaired the antitumor 
activity of preoperative ketorolac (Figure 2C).
The importance of COX-1 inhibition in cancer is poorly char-
acterized and has not been translated to cancer patients (38). TXA2 
synthesis is independent of COX-2 (90), which is consistent with 
our finding that the antitumor activity of preoperative ketorolac 
is mediated by COX-1/TXA2 inhibition. In addition, 20% of mice 
treated preoperatively with the antiplatelet agent clopidogrel 
demonstrated long-term survival in our tumor-resection model, 
consistent with reports showing that clopidogrel prevents carcino-
genesis by restoring antitumor immunity, including increasing the 
number of tissue CD8+ T cells (91). Clopidogrel also stimulates 
CD4+ and CD25+ T cells in an atherosclerosis model (92). Stud-
ies suggest a direct role for TXA2 in dendritic cell maturation and 
neutrophil migration (90), which may account for our genetic and 
pharmacologic data on the role of the TXA2 receptor in reducing 
postresection tumor recurrence.
Our findings have important therapeutic implications. First, 
ketorolac may increase long-term survival in multiple cancer 
types if administered preoperatively, rather than postoperatively, 
per current standards of care. Second, while ketorolac is a simple, 
inexpensive, and relatively nontoxic treatment, potential con-
cerns include the risk of bleeding, wound dehiscence, and acute 
kidney injury. These side effects were not noted in a human ret-
rospective study (34). In contrast, SPMs dampen inflammatory 
mediator release from platelets and do not appear to increase the 
risk of bleeding nor to enhance the hemostatic function of plate-
lets (12, 93). In our animal studies, ketorolac and resolvins demon-
strated synergistic antitumor activity without overt toxicity. Third, 
our results suggest that coadministration of preoperative ketorolac 
and immune checkpoint inhibitors may provide optimal therapeu-
tic efficacy, consistent with recent studies (2, 24, 25). High-risk 
stage III melanoma may be an ideal setting to assess the potential 
therapeutic benefit of combining ketorolac and checkpoint inhib-
itors, as checkpoint inhibitors alone have been shown to decrease 
risk of recurrence (94). Fourth, although adjuvant chemotherapy 
increases overall survival in select cancer patients, it may also har-
bor inherent tumor-promoting activity (9, 10, 18, 95–97) limiting 
its overall efficacy, including inflammation-associated impair-
ment of antitumor immunity that could stimulate micrometastatic 
disease. Indeed, administration of chemotherapy within 7 days of 
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Adoptive transfer. Splenocytes were obtained as follows: spleens 
from preoperative ketorolac-treated mice after LLC resection or age-
matched naive C57BL/6J mice were dissociated and filtered through 
40 μm strainers. CD8α+ T cells were isolated from this population by 
magnetic selection using a mouse CD8α+ T Cell Isolation Kit (Miltenyi 
Biotec). Splenocytes or isolated CD8α+ T cells were stained with CD8α 
APC-conjugated antibody (clone 53-6.7; R&D systems) and CD3 
FITC-conjugated antibody (clone 17A2; BioLegend). Staining was 
assessed via BD LSR Fortessa (BD Biosciences) at the DFCI Cytom-
etry Core and analyzed using FlowJo software (Tree Star Inc.). Sple-
nocytes (6 × 107 cells/mouse) or isolated CD8α+ T cells (3 × 106 cells/
mouse) were intravenously injected into C57BL/6J mice.
Immunohistochemistry. Slides were incubated with FOXP3+, CD4+, 
or CD8+ (Abcam; 1:100) at 4°C overnight. TSA Biotin (PerkinElmer) was 
used for signal amplification. The Zeiss A1 Scope, Axiocam ICc5, and 
Zeiss efficient navigation software (Zeiss) were used for imaging slides 
(10–20 fields/tumor). Immune cells per field were quantified via ImageJ.
LC-MS/MS. Plasma from preoperative ketorolac-treated and con-
trol mice after LLC resection was analyzed as described (99), with a 
Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector 
(Shimadzu Corp.) paired with a QTrap 6500 (ABSciex).
scRNA-Seq analysis. Spleens from control and preoperative ketoro-
lac-treated mice at 7 days after LLC resection were processed using the 
10× genomics approach. Single-cell libraries were prepared using the 
Chromium 3′ reagent kit v2 and sequenced using NextSeq 500 plat-
form to generate approximately 50,000 reads/cell. scRNA-Seq data 
after standard quality control was aligned to the reference genome 
(mm10) using the 10× Cell Ranger pipeline. Preprocessed and filtered 
normalized data were subjected to unsupervised analysis using PCA 
(Seurat v2.0 Bioconductor package; ref. 100) to identify principal 
components with significant variation that was used as input for tSNE 
analysis (101) to determine overall relationship among cells. Cells 
with similar transcriptome profiles were clustered together, and the 
clusters were subsequently annotated to different cell types based on 
expression of specific transcripts, e.g., T cells (Cd3d+), B cells (Cd19+, 
Cd79a+, C79b+, etc.). Transcripts significantly associated with a par-
ticular cell type were identified by comparing the expression profile of 
the target cell with the rest of the cells using nonparametric Wilcox’s 
rank test (P < 0.01) and fold change (>1.2).
Identification of treatment-altered genes and pathways in specific cell 
types. To determine the effect of treatment on specific cell types, com-
parative analysis of cell abundance was performed on the control and 
ketorolac-treated samples. Comparative analysis of the transcriptome 
profiles of each cell type between ketorolac-treated and control groups 
was performed using a linear model for microarray analysis approach in 
R language (102). Pathways/Functions enrichment and systems biology 
analyses using the Ingenuity Pathway Analysis software package (IPA 
9.0; QIAGEN) were performed on transcripts that were significantly 
associated with different T cell and granulocyte clusters or differentially 
expressed in the same cell types between treatment and control groups.
Statistic. For in vivo experiments, Student’s t test and ANOVA 
were utilized. Student’s t test was utilized to evaluate significance of 
in vitro experiments. The Kolmogorov-Smirnov test was used to eval-
uate the assumption of normality of continuous variables, and no sig-
nificant departures from normality were detected. Summary data are 
reported as mean ± SEM. Longitudinal tumor growth data were ana-
lyzed using 2-factor repeated-measures mixed effects ANOVA with 
Methods
Tumor resection. Tumors were resected at 1500–2000 mm3. 106 LLC 
cells (ATCC) were subcutaneously injected into male C57BL/6J, SCID, 
athymic C57BL/6J, TP KO, WT, or COX-2–KO mice (Jackson Labo-
ratory). Experiments were repeated 3 times with similar results. For 
orthotopic tumors, 5 × 104 4T1 (ATCC) or E0771 (CH3 BioSystems) 
were injected into the fourth mammary fat pad of female BALB/cJ or 
C57BL/6J mice, respectively.
Drug administration. Drugs were administered preoperatively (2 
hours before surgery), at the time of surgery, or postoperatively (2 
hours after surgery). For chemotherapy, mice were treated with pre-
operative ketorolac (7.5 mg/kg) and a postoperative dose of cisplatin 
(5 mg/kg) on day 7 after tumor resection. For immune-checkpoint 
blockade, mice were treated preoperatively with anti-mouse PD-1 
(CD279; clone RMP1-14) (200 μg/mouse; Bio X Cell). For COX inhi-
bition, mice were treated preoperatively with FR122047 (20 mg/
kg), TFAP (30 mg/kg), SC-560 (30 mg/kg), celecoxib (60 mg/kg), 
indomethacin (3 mg/kg), ibuprofen (30 mg/kg), diclofenac (10 mg/
kg), or aspirin (10 or 30 mg/kg). For TXA2 inhibition, mice were 
treated preoperatively with terutroban (30 mg/kg), U-46619 (2 μg/
kg), or clopidogrel (10 mg/kg). For T cell depletion, anti-mouse CD4 
(clone GK1.5), anti-mouse CD8 (clone 53-6.72), or isotype control 
(rat IgG2b) obtained from Bio X Cell was utilized (200 μg/mouse q 
3 days, i.p.). For PGE2 studies, mice were treated preoperatively with 
ketorolac and a PGE2-neutralizing antibody (Cayman Chemical) 
(200 μg/mouse q 3 days) or isotype control (rat IgG2b). Resolvins 
(RvD2, RvD3, or RvD4) (15 ng/d/mouse) were administered via 
miniosmotic pump (Alzet Inc.) 2 hours prior to tumor resection 
or laparotomy. Meloxicam SR was administered after surgery per 
IACUC-approved protocol.
Laparotomy. C57BL/6J or RAG1-KO male mice (Jackson Labora-
tory) were injected with 104 LLC, 103 B16F10, or 104 EL4 cells and sub-
jected to laparotomy under isoflurane inhalation anesthesia. Bowels 
were removed, placed on a sterile sheet for 4 minutes, and returned 
to the peritoneum. The skin was sutured with 4-0 chromic gut absorb-
able sutures. Tumor size was measured by caliper (width2 × length × 
0.52 = mm3).
Chemotherapy-stimulated cancer. For dormancy models, 104 LLC, 
EL4, or CT26 cells (ATCC) were subcutaneously injected into male 
C57BL/6J (LLC and EL4) or BALB/cJ (CT26) mice. Cisplatin (5 mg/kg 
q 5 days), vincristine (1 mg/kg q 7 days), or 5-FU treatment (30 mg/kg 
q 3 days) was initiated on the day of tumor cell injection. For combina-
tion therapies, ketorolac (7.5 mg/kg) was administered the day before, 
day of, and day after cisplatin or vincristine as well as the day before 
and day of 5-FU treatment.
Tumor rechallenge. Preoperative ketorolac- or RvD2-treated mice 
that survived 90 days after LLC resection and naive age-matched 
mice were challenged with 106 LLC via subcutaneous injection. On 
day 90 after LLC rechallenge, the LLC tumor-resected mice treated 
with preoperative ketorolac or RvD2, which did not grow tumors, were 
subcutaneously injected with 106 B16F10.
Preoperative ketorolac-treated LLC tumor-bearing mice (104 
cells) were subjected to a laparotomy. Ninety days after laparotomy, 
these mice and naive age-matched mice were challenged with 106 LLC 
via subcutaneous injection. On day 90 after LLC rechallenge, the pre-
operative ketorolac-treated mice subjected to laparotomy, which did 
not grow tumors, were subcutaneously injected with 106 B16F10.
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